RedHill Biopharma Stock Price, News & Analysis (NASDAQ:RDHL) $2.28 +1.28 (+128.00%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$1.17▼$2.7950-Day Range$0.31▼$2.2852-Week Range$0.26▼$15.20Volume152.67 million shsAverage Volume9.92 million shsMarket Capitalization$25.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media About RedHill Biopharma Stock (NASDAQ:RDHL)RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.Read More RDHL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RDHL Stock News HeadlinesNovember 27, 2023 | investorplace.com5 Investors Betting Big on RedHill Biopharma (RDHL) StockNovember 27, 2023 | msn.comWhy Is Gastrointestinal Disease Focused-RedHill Biopharma Stock Higher Over 100% Today?November 29, 2023 | Edge On The Street (Ad)An Unusual Way to Invest in GoldMost financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines. November 27, 2023 | markets.businessinsider.comRedHill's Talicia Granted 5-year Market Exclusivity By FDANovember 27, 2023 | finance.yahoo.comRedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034November 22, 2023 | americanbankingnews.comRedHill Biopharma (NASDAQ:RDHL) Now Covered by Analysts at StockNews.comNovember 22, 2023 | finance.yahoo.comRedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital MarketOctober 19, 2023 | benzinga.comThe Street Reports: Guide to Penny Stocks Look Now! CLNV, ARAV, RDHL, ATHX, EPAZNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 3, 2023 | msn.comIsrael-Based Penny Stock RedHill Biopharma Is Trading Higher Today - Here's Why?October 3, 2023 | finance.yahoo.comRedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo StudySeptember 5, 2023 | finance.yahoo.comRedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)August 17, 2023 | finance.yahoo.comRedHill Biopharma Provides H1/23 Financial Results and Operational HighlightsJuly 31, 2023 | finance.yahoo.comRedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDAJuly 25, 2023 | finance.yahoo.comRedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant ExerciseJuly 21, 2023 | benzinga.comWhat's Going On With RedHill Biopharma Stock TodayJuly 21, 2023 | finance.yahoo.comRedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross ProceedsJuly 21, 2023 | finance.yahoo.comRedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure DevelopmentJuly 6, 2023 | technews.tmcnet.comPhil and RedHill Biopharma Partner to Increase Access to Talicia®June 12, 2023 | finanznachrichten.deRedHill Biopharma Ltd.: RedHill Biopharma Announces Q1/2023 Financial Results and Operational HighlightsJune 12, 2023 | finance.yahoo.comRedHill Biopharma Announces Q1/2023 Financial Results and Operational HighlightsMay 24, 2023 | bizjournals.comRaleigh drug developer trims R&D pipeline, shifts resourcesMay 22, 2023 | finance.yahoo.comRedHill Provides R&D UpdateMay 15, 2023 | finance.yahoo.comRedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares DeficiencyMay 9, 2023 | finance.yahoo.comRedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease WeekMay 1, 2023 | finance.yahoo.comRedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology SettingApril 28, 2023 | finanznachrichten.deRedHill Biopharma Ltd.: RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational HighlightsSee More Headlines Receive RDHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/30/2021Today11/29/2023Next Earnings (Estimated)12/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RDHL CUSIPN/A CIK1553846 Webwww.redhillbio.com Phone972-3541-3131Fax972-3541-3144Employees113Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,670,000.00 Net Margins354.95% Pretax Margin-9.10% Return on Equity-328.99% Return on Assets71.39% Debt Debt-to-Equity RatioN/A Current Ratio0.96 Quick Ratio0.78 Sales & Book Value Annual Sales$61.80 million Price / Sales0.41 Cash FlowN/A Price / Cash FlowN/A Book Value($16.41) per share Price / Book-0.14Miscellaneous Outstanding Shares11,070,000Free Float10,317,000Market Cap$25.24 million OptionableOptionable Beta2.14 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Dror Ben-Asher (Age 57)Co-Founder, CEO & Director Comp: $734.59kMr. Gilead Raday MPhil (Age 48)MSc, Chief Operating Officer Comp: $445.38kMr. Adi Frish (Age 53)Chief Corporate & Business Development Officer Comp: $419.5kMr. Rick D. Scruggs (Age 63)Chief Commercial Officer, President of RedHill Biopharma Inc. & Director Comp: $607.05kMr. Razi Ingber (Age 39)Chief Financial Officer Ms. Alexandra OkmianSenior Business Development & Investor Relations ManagerDr. Reza Fathi Ph.D. (Age 68)Senior Vice President of Research & Development Comp: $299.29kMr. Guy Goldberg (Age 47)Chief Business Officer Comp: $338.13kMs. Patricia Anderson B.Sc. RACSenior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsCumberland PharmaceuticalsNASDAQ:CPIXMedicenna TherapeuticsNASDAQ:MDNANuCanaNASDAQ:NCNAvTv TherapeuticsNASDAQ:VTVTRegulus TherapeuticsNASDAQ:RGLSView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 722,894 shares on 11/15/2023Ownership: 6.530%Sabby Management LLCBought 635,006 shares on 11/15/2023Ownership: 5.736%View All Institutional Transactions RDHL Stock Analysis - Frequently Asked Questions How have RDHL shares performed in 2023? RedHill Biopharma's stock was trading at $5.6120 on January 1st, 2023. Since then, RDHL stock has decreased by 59.4% and is now trading at $2.28. View the best growth stocks for 2023 here. Are investors shorting RedHill Biopharma? RedHill Biopharma saw a drop in short interest in November. As of November 15th, there was short interest totaling 29,100 shares, a drop of 90.1% from the October 31st total of 293,600 shares. Based on an average trading volume of 4,720,000 shares, the short-interest ratio is presently 0.0 days. Approximately 0.3% of the shares of the company are short sold. View RedHill Biopharma's Short Interest. When is RedHill Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 5th 2023. View our RDHL earnings forecast. How were RedHill Biopharma's earnings last quarter? RedHill Biopharma Ltd. (NASDAQ:RDHL) announced its quarterly earnings data on Tuesday, November, 30th. The biotechnology company reported ($20.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($19.20) by $0.80. The biotechnology company earned $21.61 million during the quarter, compared to analyst estimates of $23.41 million. RedHill Biopharma had a net margin of 354.95% and a negative trailing twelve-month return on equity of 328.99%. During the same quarter in the previous year, the business posted ($20.00) earnings per share. When did RedHill Biopharma's stock split? Shares of RedHill Biopharma reverse split before market open on Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of RedHill Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA). Who are RedHill Biopharma's major shareholders? RedHill Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (6.53%), Sabby Management LLC (5.74%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of RedHill Biopharma? Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:RDHL) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RedHill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.